Preeclampsia and HELLP syndrome: Impaired mitochondrial function in umbilical endothelial cells

Reproductive Sciences

Volumn 17, Issue 3, 2010, Pages 219-226

  Illsinger, Sabine ^a   Janzen, Nils ^a,b   Sander, Stefanie ^b   Schmidt, Karl Heinz ^a   Bednarczyk, Jolanthe ^a   Mallunat, Lisa ^a   Bode, Julia ^a   Hagebölling, Friederike ^a   Hoy, Ludwig ^a   Lücke, Thomas ^a   Hass, Ralf ^a   Das, Anibh M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Screening Laboratory Hannover   (Germany)

Author keywords

Fatty acid oxidation; HELLP syndrome; Mitochondrial energy metabolism; Preeclampsia; Respiratory chain

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ACYLCARNITINE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CITRATE SYNTHASE; CYTOCHROME C OXIDASE; HEXOKINASE; LACTATE DEHYDROGENASE; PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIUM CELL; ENERGY METABOLISM; ENZYME ACTIVITY; FATTY ACID OXIDATION; FEMALE; FETOPLACENTAL UNIT; FETUS; FETUS DISEASE; HELLP SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PUERPERIUM; RESPIRATORY CHAIN; UMBILICAL VEIN; UMBILICUS; UPREGULATION;

ADULT; CARNITINE; CARNITINE O-PALMITOYLTRANSFERASE; CITRATE (SI)-SYNTHASE; ELECTRON TRANSPORT; ENDOTHELIAL CELLS; ENERGY METABOLISM; FATTY ACIDS; FEMALE; GLYCOLYSIS; HELLP SYNDROME; HUMANS; INFANT, NEWBORN; L-LACTATE DEHYDROGENASE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MULTIENZYME COMPLEXES; OXIDATION-REDUCTION; PHOSPHOFRUCTOKINASES; PRE-ECLAMPSIA; PREGNANCY; UMBILICAL VEINS;

EID: 77949455431     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719109351597     Document Type: Article

References (42)

1. Baxter JK, Weinstein L. HELLP syndrome: the state of the art. Obstet Gynecol Surv. 2004 ; 59 (12). 838-845.
2. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005 ; 365 (9461). 785-799.
3. Brown MA, Hague WM, Higgins J., et al., and the Austalasian Society for the Study of Hypertension in Pregnancy. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol. 2000 ; 40 (2). 139-155.
4. Ibdah JA, Bennett MJ, Rinaldo P., et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med. 1999 ; 340 (22). 1723-1731.
5. Strauss AW, Bennett MJ, Rinaldo P., et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin Perinatol. 1999 ; 23 (2). 100-112.
6. Schoeman MN, Batey RG, Wilcken B. Recurrent acute fatty liver of pregnancy associated with a fatty-acid oxidation defect in the offspring. Gastroenterology. 1991 ; 100 (2). 544-548.
7. Mutze S., Ahillen I., Rudnik-Schoeneborn S., et al. Neither maternal nor fetal mutation (E474Q) in the alpha-subunit of the trifunctional protein is frequent in pregnancies complicated by HELLP syndrome. J Perinat Med. 2007 ; 35 (1). 76-78.
8. Wang R., Yang Z., Zhu JM, et al. Screening for G1528C mutation in mitochondrial trifunctional protein gene in pregnant women with severe preeclampsia and new born infant [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2006 ; 41 (10). 672-675.
9. Yang Z., Yamada J., Zhao Y., Strauss AW, Ibdah JA Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease. JAMA. 2002 ; 288 (17). 2163-2166.
10. den Boer ME, Ijlst L., Wijburg FA, et al. Heterozygosity for the common LCHAD mutation (1528g>C) is not a major cause of HELLP syndrome and the prevalence of the mutation in the Dutch population is low. Pediatr Res. 2000 ; 48 (2). 151-154.
11. Holub M., Bodamer OA, Item C., Muhl A., Pollak A., Stockler-Ipsiroglu S. Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? Acta Paediatr. 2005 ; 94 (1). 48-52.
12. Illsley NP Glucose transporters in the human placenta. Placenta. 2000 ; 21 (1). 14-22.
13. Faivre L., Cormier-Daire V., Chretien D., et al. Determination of enzyme activities for prenatal diagnosis of respiratory chain deficiency. Prenat Diagn. 2000 ; 20 (9). 732-737.
14. Shekhawat P., Bennett MJ, Sadovsky Y., Nelson DM, Rakheja D., Strauss AW Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Physiol Endocrinol Metab. 2003 ; 284 (6). E1098 - E1105.
15. Rakheja D., Bennett MJ, Foster BM, Domiati-Saad R., Rogers BB Evidence for fatty acid oxidation in human placenta, and the relationship of fatty acid oxidation enzyme activities with gestational age. Placenta. 2002 ; 23 (5). 447-450.
16. Oey NA, Ruiter JP, Attie-Bitach T., Ijlst L., Wanders RJ, Wijburg FA Fatty acid oxidation in the human fetus: implications for fetal and adult disease. J Inherit Metab Dis. 2006 ; 29 (1). 71-75.
17. Knopp RH, Warth MR, Charles D., et al. Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes. Biol Neonate. 1986 ; 50 (6). 297-317.
18. Thiele IG, Niezen-Koning KE, van Gennip AH, Aarnoudse JG Increased plasma carnitine concentrations in preeclampsia. Obstet Gynecol. 2004 ; 103 (5 pt 1). 876-880.
19. Torbergsen T., Oian P., Mathiesen E., Borud O. Pre-eclampsia-a mitochondrial disease? Acta Obstet Gynecol Scand. 1989 ; 68 (2). 145-148.
20. He L., Wang Z., Sun Y. Reduced amount of cytochrome c oxidase subunit I messenger RNA in placentas from pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand. 2004 ; 83 (2). 144-148.
21. Matsubara S., Minakami H., Sato I., Saito T. Decrease in cytochrome c oxidase activity detected cytochemically in the placental trophoblast of patients with pre-eclampsia. Placenta. 1997 ; 18 (4). 255-259.
22. Wang Z., Zhang G., Lin M. Mitochondrial tRNA(leu) (UUR) gene mutation and the decreased activity of cytochrome c oxidase in preeclampsia. J Tongji Med Univ. 1999 ; 19 (3). 209-211.
23. Magann EF, Martin JN Jr. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol. 1999 ; 42 (3). 532-550.
24. Martin JN Jr, Blake PG, Perry KG Jr, McCaul JF, Hess LW, Martin RW The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol. 1991 ; 164 (6 pt 1). 1500-1509 ; ; discussion 1509-1513.
25. Ulrich-Merzenich G., Metzner C., Bhonde RR, Malsch G., Schiermeyer B., Vetter H. Simultaneous isolation of endothelial and smooth muscle cells from human umbilical artery or vein and their growth response to low-density lipoproteins. In Vitro Cell Dev Biol Anim. 2002 ; 38 (5). 265-272.
26. Wanders RJ, Vreken P., den Boer ME, Wijburg FA, van Gennip AH, IJlst L. Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis. 1999 ; 22 (4). 442-487.
27. Demaugre F., Bonnefont JP, Mitchell G., et al. Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities. Pediatr Res. 1988 ; 24 (3). 308-311.
28. Das AM Regulation of mitochondrial ATP synthase activity in human myocardium. Clin Sci (Lond). 1998 ; 94 (5). 499-504.
29. Srere PA Citrate synthase. EC 4.1.3.7. Citrate oxaloacetatelyase (CoA-acetylation). In: Colowich SP, Kaplan NO, eds. Methods Enzymology XIII. New York. Academic Press ; 1969 ; 3-11.
30. Das AM, von Harlem R., Feist M., Lucke T., Kohlschutter A. Altered levels of high-energy phosphate compounds in fibroblasts from different forms of neuronal ceroid lipofuscinoses: further evidence for mitochondrial involvement. Eur J Paediatr Neurol. 2001 ; 5 (suppl A). 143-146.
31. Chace DH, Kalas TA, Naylor EW Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003 ; 49 (11). 1797-1817.
32. Vuorinen K., Remes A., Sormunen R., Tapanainen J., Hassinen IE Placental mitochondrial DNA and respiratory chain enzymes in the etiology of preeclampsia. Obstet Gynecol. 1998 ; 91 (6). 950-955.
33. Yulug E., Yenilmez E., Unsal MA, Aydin S., Tekelioglu Y., Arvas H. Apoptotic and morphological features of the umbilical artery endothelium in mild and severe pre-eclampsia. Acta Obstet Gynecol Scand. 2006 ; 85 (9). 1038-1045.
34. Scarpulla RC Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci. 2008 ; 1147: 321-334.
35. Ventura FV, Ruiter JP, Ijlst L., de Almeida IT, Wanders RJ Inhibitory effect of 3-hydroxyacyl-CoAs and other long-chain fatty acid beta-oxidation intermediates on mitochondrial oxidative phosphorylation. J Inherit Metab Dis. 1996 ; 19 (2). 161-164.
36. ter Veld F., Primassin S., Hoffmann L., Mayatepek E., Spiekerkoetter U. Corresponding increase in long-chain acyl-CoA and acylcarnitine after exercise in muscle from VLCAD mice. J Lipid Res. 2009 ; 50 (8). 1556-1562.
37. Koumantakis E., Sifakis S., Koumantaki Y., et al. Plasma carnitine levels of pregnant adolescents in labor. J Pediatr Adolesc Gynecol. 2001 ; 14 (2). 65-69.
38. Oey NA, van Vlies N., Wijburg FA, Wanders RJ, Attie-Bitach T., Vaz FM l-Carnitine is synthesized in the human fetal-placental unit: potential roles in placental and fetal metabolism. Placenta. 2006 ; 27 (8). 841-846.
39. Rytting E., Audus KL Effects of low oxygen levels on the expression and function of transporter OCTN2 in BeWo cells. J Pharm Pharmacol. 2007 ; 59 (8). 1095-1102.
40. Slaghekke F., Dekker G., Jeffries B. Endogenous inhibitors of nitric oxide and preeclampsia: a review. J Matern Fetal Neonatal Med. 2006 ; 19 (8). 447-452.
41. Knapen MF, Peters WH, Mulder TP, Merkus HM, Jansen JB, Steegers EA Glutathione and glutathione-related enzymes in decidua and placenta of controls and women with preeclampsia. Placenta. 1999 ; 20 (7). 541-546.
42. Teran E., Vivero S., Racines-Orbe M., et al. Coenzyme Q10 is increased in placenta and cord blood during preeclampsia. Bio-factors. 2005 ; 25 (1-4). 153-158.